Table 4.
Infected | Vaccinated | ||||||
---|---|---|---|---|---|---|---|
N | Median [IQR] | n | Median [IQR] | p-value | |||
IgA antibody titres against RBD | |||||||
Overall | 52 | 2.97 [1.55; 7.37] | 102 | 2.91 [1.61; 4.94] | 0.39 | ||
KTR | 17 | 7.09 [2.28; 10.09] | 57 | 3.11 [1.75; 4.70] | 0.009 | ||
HD | 18 | 2.19 [1.45; 6.75] | 38 | 2.99 [1.87; 6.64] | 0.54 | ||
Control | 17 | 2.64 [1.60; 5.08] | 7 | 1.46 [1.20; 1.54] | 0.01 | ||
IgA antibody titres against S1S2 | |||||||
Overall | 60 | 5.82 [2.75; 14.10] | 122 | 2.29 [1.41; 4.15] | < 0.001 | ||
KTR | 19 | 12.41 [2.78; 21.10] | 57 | 2.43 [1.57; 3.42] | < 0.001 | ||
HD | 21 | 4.66 [2.54; 11.84] | 50 | 2.29 [1.38; 4.32] | 0.01 | ||
Control | 20 | 4.41 [2.80; 8.05] | 15 | 1.61 [1.24; 4.15] | 0.004 |
Table showing the IgA antibody titres directed to RBD (upper panel) and S1S2 (lower panel) of SARS-CoV-2 in responders. Time from PCR or first vaccine to blood sample was not correlated with the IgA RBD titres (n = 154, rs = 0.02, p = 0.82) nor IgA S1S2 titres (n = 182, rs = -0.08, p = 0.27). KTR Kidney transplant recipients, HD hemodialysis